Trials / Completed
CompletedNCT02881138
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC48-ADC for Injection in Subjects With Advanced Malignant Solid Tumors With HER2-positive
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC48-ADC |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2020-04-30
- Completion
- 2020-07-15
- First posted
- 2016-08-26
- Last updated
- 2020-07-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02881138. Inclusion in this directory is not an endorsement.